MegWei Bio-B (02493) elects Liu Datao as chairman.
Miwei Biotech-B (02493) announced that Mr. Hu Huiguo will retire as an executive director, Mr. Wu Yufeng will retire as a non-executive director, Dr. Xu Qing and Dr. Zhao Qian will retire as independent non-executive directors, with effect from June 18, 2026, as their terms will expire on June 20, 2026.
Meiwei Bio-B (02493) announced that Mr. Hu Huiguo will retire as an executive director, Mr. Wu Yufeng will retire as a non-executive director, and Dr. Xu Qing and Dr. Zhao Qian will retire as independent non-executive directors when their terms end on June 20, 2026, with effect from June 18, 2026.
The election of Mr. Tang Chunshan, Dr. Liu Datao, Dr. Wu Hai, and Mr. Hua Jun as executive directors of the third board of directors, and the election of Mr. Qin Zhengyu, Mr. Zhou Rui, Ms. Li Fan, and Ms. Wang Fang as independent non-executive directors of the third board of directors has come into effect at the extraordinary general meeting held on June 18, 2026.
The first meeting of the third board of directors was held on June 18, 2026, during which the following resolutions were discussed and passed: (1) election of Dr. Liu Datao as chairman of the board; (2) establishment of the following committees under the third board of directors and appointment of chairpersons and members for each committee:
(i) establishment of the audit committee, consisting of three independent non-executive directors, namely Mr. Qin Zhengyu (chairman of the audit committee), Mr. Zhou Rui, and Ms. Li Fan;
(ii) establishment of the remuneration and assessment committee, consisting of one executive director (Dr. Liu Datao) and two independent non-executive directors (Mr. Zhou Rui and Ms. Li Fan (chairperson of the remuneration and assessment committee));
(iii) establishment of the nomination committee, consisting of one executive director (Dr. Liu Datao) and two independent non-executive directors (Mr. Zhou Rui (chairman of the nomination committee) and Ms. Li Fan);
(iv) establishment of the strategic committee, consisting of three executive directors (Dr. Liu Datao (chairman of the strategic committee), Mr. Tang Chunshan, and Dr. Wu Hai);
(v) establishment of the ESG committee, consisting of two executive directors (Dr. Liu Datao (chairman of the ESG committee) and Mr. Hua Jun) and one independent non-executive director (Ms. Li Fan).
Related Articles

GET NICE (00064) announces annual performance, with a net profit attributable to shareholders of HK$53.387 million, a year-on-year increase of 29.66%.

Mindray Bio-Medical (02493): The latest clinical data of 9MW2821 will be reported in oral and poster forms at the 2026 European Society of Medical Oncology (ESMO) Gynecologic Oncology Annual Meeting.

DAWNRAYS PHARMA (02348) plans to invest 100 million yuan to establish a partnership enterprise for equity investment in the fields of medicine, biotechnology, and medical health.
GET NICE (00064) announces annual performance, with a net profit attributable to shareholders of HK$53.387 million, a year-on-year increase of 29.66%.

Mindray Bio-Medical (02493): The latest clinical data of 9MW2821 will be reported in oral and poster forms at the 2026 European Society of Medical Oncology (ESMO) Gynecologic Oncology Annual Meeting.

DAWNRAYS PHARMA (02348) plans to invest 100 million yuan to establish a partnership enterprise for equity investment in the fields of medicine, biotechnology, and medical health.

RECOMMEND





